Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Recommendation of "Hold" from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) has been assigned an average rating of "Hold" from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $15.83.

ELAN has been the subject of several analyst reports. Stifel Nicolaus lowered their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a report on Friday, February 21st. Leerink Partnrs upgraded shares of Elanco Animal Health to a "hold" rating in a report on Monday, December 2nd. Leerink Partners initiated coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They set a "market perform" rating and a $14.00 price target for the company. Barclays lowered their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday. Finally, Morgan Stanley lowered their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday.

Elanco Animal Health Stock Up 2.4 %

Shares of NYSE ELAN opened at $11.19 on Friday. The company has a 50 day simple moving average of $11.71 and a 200 day simple moving average of $13.03. The firm has a market cap of $5.53 billion, a PE ratio of 27.96, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a 1 year low of $10.20 and a 1 year high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm's quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.08 EPS. On average, research analysts forecast that Elanco Animal Health will post 0.91 EPS for the current year.

Institutional Trading of Elanco Animal Health

Hedge funds have recently modified their holdings of the stock. CoreCap Advisors LLC bought a new stake in shares of Elanco Animal Health in the 4th quarter valued at $29,000. AM Squared Ltd bought a new stake in shares of Elanco Animal Health in the 3rd quarter valued at $34,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Elanco Animal Health in the 3rd quarter valued at $35,000. Farther Finance Advisors LLC increased its stake in shares of Elanco Animal Health by 158.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company's stock valued at $49,000 after acquiring an additional 2,044 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its stake in shares of Elanco Animal Health by 89.9% in the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company's stock valued at $50,000 after acquiring an additional 1,601 shares in the last quarter. Institutional investors own 97.48% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.